Clinical Trial Detail

NCT ID NCT02477826
Title An Open-Label, Trial of Nivolumab and Nivolumab Plus Ipilimumab Versus Platinum Doublet Chemotherapy in Subjects With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

lung non-small cell carcinoma

Therapies

Nivolumab

Cisplatin

Ipilimumab

Pemetrexed Disodium

Carboplatin

Gemcitabine

Age Groups: adult

No variant requirements are available.